Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation
Francesca Lorentino, Elisabetta Xue, Sara Mastaglio, Fabio Giglio, Daniela Clerici, Francesca Farina, Simona Piemontese, Alessandro Bruno, Lorenzo Lazzari, Annalisa Ruggeri, Elena Guggiari, Francesca Lunghi, Andrea Assanelli, Sarah Marktel, Magda Marcatti, Matteo Giovanni Carrabba, Massimo Bernardi, Consuelo Corti, Jacopo Peccatori, Fabio Ciceri, Raffaella Greco, Maria Teresa Lupo Stanghellini
Abstract
Among major unmet needs in allogeneic stem cell transplantation (HSCT), the identification of a suitable donor, the control of infection complications (where cytomegalovirus [CMV] is paradigmatic), and the reduction of both disease relapse and graft-versus-host disease (GVHD) represent 4 key challenges.
Topics & Concepts
MedicineGraft-versus-host diseaseHematopoietic stem cell transplantationCalcineurinCohortInternal medicineInterquartile rangeTransplantationTacrolimusCytomegalovirusPopulationImmunologySirolimusVirusHerpesviridaeViral diseaseEnvironmental healthCytomegalovirus and herpesvirus researchHematopoietic Stem Cell TransplantationPolyomavirus and related diseases